ZBIO — Zenas Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $498.25m
- $147.48m
- $5.00m
- 27
- 11
- 39
- 14
Annual balance sheet for Zenas Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 67.2 | 56.9 | 351 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 68.4 | 59.8 | 356 |
| Net Property, Plant And Equipment | 1.8 | 1.01 | 1.19 |
| Other Long Term Assets | |||
| Total Assets | 74.6 | 68.2 | 370 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 26 | 23.3 | 57.3 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 26.8 | 43.8 | 57.5 |
| Redeemable Preferred Stock | |||
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 47.8 | 24.4 | 312 |
| Total Liabilities & Shareholders' Equity | 74.6 | 68.2 | 370 |
| Total Common Shares Outstanding |